Tier 2 — strong

Coenzyme Q10 Impact on Ovarian Reserve Measures and the Intra-Cytoplasmic Sperm Injection (ICSI) Outcomes in Women with Poor Ovarian Response: A Randomized Controlled Study

Mona A Abdelrahman, Mayar Gamal, Sara A Salem, Ahmed R N Ibrahim, Hoda Rabea
Drug Design, Development and Therapy 2026 20:583321

Bibliography

PubMed
PMID 41800295
PubMed Central
PMC12965276
DOI
10.2147/DDDT.S583321
Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
King Khalid University Deanship of Scientific Research and Graduate Studies, grant RGP1/59/46.
Competing interests
The authors declared no conflicts of interest.

Study snapshot

DesignProspective open-label randomized controlled trial
ModelHuman; women with poor ovarian response by Bologna criteria undergoing ICSI
Sample100
InterventionCoQ10 200 mg twice daily (400 mg/day) plus folic acid 500 µg versus folic acid 500 µg alone, beginning before ICSI.
DurationInitial 1 month before ICSI and continued through the ICSI cycle.
EndpointsRetrieved oocytes; Antral follicle count; Peak estradiol; Endometrial thickness; Chemical pregnancy; Clinical pregnancy

What the study showed, in plain terms

This 2026 randomized trial tested CoQ10 pretreatment in 100 women with poor ovarian response undergoing ICSI. CoQ10 improved several ovarian-response and cycle measures, including the number of retrieved oocytes, but chemical and clinical pregnancy rates were not significantly different and live birth was not studied.

Key findings

Women randomized to 400 mg/day CoQ10 plus folic acid had better ovarian-response measures, including retrieved-oocyte count, peak estradiol, antral follicle count, and endometrial thickness. Chemical and clinical pregnancy outcomes were not significantly improved.

What this study can and cannot tell us

The trial included only 100 participants and was open-label, which can introduce performance and measurement bias. Pregnancy outcomes were secondary and live birth was not assessed. Improvements in ovarian-response markers should not be equated with proven improvement in live birth.

Related papers in the corpus

Tier 2
Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial
Yangying Xu et al. · Reproductive Biology and Endocrinology · 2018
Tier 2
Does coenzyme Q10 supplementation improve fertility outcomes in women undergoing assisted reproductive technology procedures? A systematic review and meta-analysis of randomized-controlled trials
Panagiota Florou et al. · Journal of Assisted Reproduction and Genetics · 2020
Tier 2
Clinical evidence of coenzyme Q10 pretreatment for women with diminished ovarian reserve undergoing IVF/ICSI: a systematic review and meta-analysis
Guangyao Lin et al. · Annals of Medicine · 2024

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology